Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

UCSD researcher shot by cofounder

On September 18, former Traversa Therapeutics CEO Hans Petersen went on a shooting spree. One of two people wounded was molecular biologist Steven Dowdy, a professor at University of California San Diego (UCSD) School of Medicine, in La Jolla, and cofounder of Traversa, according to a San Diego police report. Petersen has pled not guilty to charges of attempted murder and awaits trial. Petersen and Dowdy set up Traversa in 2006 to commercialize two promising short-interfering RNA (siRNA) delivery technologies licensed from Dowdy's UCSD laboratory. In 2010 the board of directors asked Petersen to leave, citing the growing complexity of operations, a decision Petersen blamed on Dowdy, according to the UCSD professor. But Dowdy says he had no vote on the board: “I was not the grand poobah of Traversa.” Petersen's protracted departure coincided with a period in which the pharma industry shied away from RNAi research (Nat. Biotechnol. 29, 93–94 (2011)). The company's main delivery technology, a fusion of a protein transduction domain and double-stranded RNA binding domain (PTD-DRBD), capable of chaperoning siRNAs through cell membranes to silence genes, only worked at low concentrations. But at the higher siRNA concentrations necessary for clinical trials, it precipitated, Dowdy says. Traversa developed an improved version by late 2011 and decided to focus on that, returning the license for the second siRNA delivery technology ribonucleic neutrals (RNNs) to UCSD. Even so, Traversa failed to attract Series C funding and in April 2012 filed for bankruptcy. Dowdy's UCSD laboratory meanwhile made more progress with RNNs. He and ex-Traversa CSO Curt Bradshaw have since launched another San Diego–based startup, Solstice Biologics, to capitalize on that technology. In January 2013 Solstice reported an $18-million Series A funding round. Dowdy is recovering from his gunshot wound and says he is “looking forward to getting back into my laboratory and doing science.”

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Laursen, L. UCSD researcher shot by cofounder. Nat Biotechnol 31, 952 (2013). https://doi.org/10.1038/nbt1113-952a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1113-952a

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing